Literature DB >> 9730795

Local and peripheral plasma endothelin-1 in pulmonary hypertension secondary to chronic obstructive pulmonary disease.

G Celik1, G Karabiyikoğlu.   

Abstract

Endothelin-1 (ET-1) has been described to have crucial effects in the initiation and evolution of pulmonary hypertension (PH) secondary to cardiac disorders. However, the precise role of ET-1 in PH induced by chronic obstructive pulmonary disease (COPD) is not yet clear. The objective of this cross-sectional study was to determine the local and peripheral plasma ET-1 profile of COPD patients with or without PH. Twenty-six COPD patients with clinical and/or laboratory findings suspicious of PH, and 20 healthy smoker volunteers constituted the study population. Patients were allocated to PH (n = 17) and non-PH (n = 9) groups according to their pulmonary artery pressures determined by right-heart catheterization. Plasma ET-1 samples, obtained from the main pulmonary artery (mixed venous blood) and peripheral blood (radial artery and brachial vein), were assessed by radioimmunoassay. Brachial vein ET-1 levels were within normal ranges in PH (2.7 +/- 0.5 pg/ml) and non-PH (3.2 +/- 0. 7 pg/ml) COPD patients compared with that of the controls (4.4 +/- 0. 1 pg/ml). Likewise, radial artery ET-1 levels in PH (3.3 +/- 0.7 pg/ml) and non-PH (2.9 +/- 0.8 pg/ml) groups, and in controls (3.4 +/- 1.1 pg/ml) were also comparable. The pulmonary artery ET-1 concentration of the PH group (13.6 +/- 3.7 pg/ml) was higher than that of the non-PH group (2.2 +/- 0.4 pg/ml) and that of the peripheral blood levels of controls. Elevated pulmonary artery ET-1 in the PH group was inversely correlated only with PaO2 levels. These results could be taken as an evidence of a local role of ET-1 in COPD-induced PH, but it remains to be clarified whether ET-1 is a marker or a mediator of PH in COPD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9730795     DOI: 10.1159/000029278

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  7 in total

1.  Relationship between coronary artery disease and pulmonary arterial pressure in patients with chronic obstructive pulmonary disease.

Authors:  Muntecep Asker; Selvi Asker; Ugur Kucuk; Hilal Olgun Kucuk; Bulent Ozbay
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going.

Authors:  Andreas Haryono; Risa Ramadhiani; Gusty Rizky Teguh Ryanto; Noriaki Emoto
Journal:  Biology (Basel)       Date:  2022-05-16

Review 3.  Cardiac disease in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Steven Kadiev; Gerard J Criner; Steven M Scharf; Omar A Minai; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 4.  Gas exchange and pulmonary hypertension following acute pulmonary thromboembolism: has the emperor got some new clothes yet?

Authors:  John Y C Tsang; James C Hogg
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

5.  Adhesion molecules, endothelin-1 and lung function in seven population-based cohorts.

Authors:  E C Oelsner; T D Pottinger; K M Burkart; M Allison; S G Buxbaum; N N Hansel; R Kumar; E K Larkin; L A Lange; L R Loehr; S J London; G T O'Connor; G Papanicolaou; M F Petrini; D Rabinowitz; S Raghavan; S Redline; B Thyagarajan; R P Tracy; J B Wilk; W B White; S S Rich; R G Barr
Journal:  Biomarkers       Date:  2013-04-05       Impact factor: 2.658

Review 6.  Role of endothelin-1 in lung disease.

Authors:  K A Fagan; I F McMurtry; D M Rodman
Journal:  Respir Res       Date:  2001-02-22

7.  Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension.

Authors:  Pierluigi Carratu; Cristina Scoditti; Mauro Maniscalco; Teresa Maria Seccia; Giuseppe Di Gioia; Felice Gadaleta; Rosa Angela Cardone; Silvano Dragonieri; Paola Pierucci; Antonio Spanevello; Onofrio Resta
Journal:  BMC Pulm Med       Date:  2008-09-26       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.